Innovent to Partner two Sanofi Cancer Assets in China; Sanofi Invests $305 Million in Innovent
publication date: Aug 5, 2022
Suzhou Innovent Biologics will develop two Sanofi cancer candidates for China use with Sanofi investing $305 million in Innovent shares. The drug candidates are (1) tusamitamab ravtansine, an anti-CEACAM5 antibody-drug conjugate in Phase III trials, and (2) non-alpha IL-2 in Phase II trials (combined with Innovent’s PD-1, sintilimab). Innovent will be responsible for China clinical development of both Sanofi candidates, but will commercialize only tusamitamab ravtansine. Sanofi will be eligible for $81 million in milestones on tusamitamab ravtansine and up to $61 million in IL-2 milestones. More details....
Stock Symbol: (HK: 01801)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.